Our Technology

NeoChord's technology is designed to treat degenerative mitral regurgitation (MR). According to the literature, degenerative MR accounts for approximately 80% of mitral surgeries and typically the valve pathology of these patients is ruptured or elongated chords.

NeoChord's proprietary technology is designed to enable the use of minimally invasive surgical techniques for the implantation of artificial chords, without the need for the sternotomy and cardiopulmonary bypass required in open heart surgery. The NeoChord procedure is performed on a beating heart which allows the surgeon to adjust the artificial chord length intra-operatively while receiving real time feedback via transesophageal echocardiography, that the regurgitation is eliminated.

In the NeoChord procedure, the heart is accessed through a left lateral thoracotomy, which is standard practice in other cardiac procedures and avoids the need for a sternotomy. The NeoChord device is then inserted through the apex of the heart into the left ventricle, using transesophageal echocardiography (TEE) to guide the surgeon. While the heart is beating, the device captures the prolapsing leaflet and attaches the artificial chord to the leaflet. The device and the attached artificial chord are then pulled back through the left ventricle to the outside of the heart. The surgeon can then visualize the function of the mitral valve leaflet using TEE and the tension of the artificial chord can be adjusted to allow for appropriate coaptation of the mitral valve leaflets. After the surgeon is satisfied that the MR has been addressed, the suture is tied off and cut. The incision is sutured and the surgery is complete.

This device is currently under clinical investigation and is not yet approved for commercial sale.